Discover more insights into Cardiorenal Outcomes 심폐 결과

Keywords frequently search together with Cardiorenal Outcomes 심폐 결과

Narrow sentence examples with built-in keyword filters

Cardiorenal Outcomes sentence examples within Adverse Cardiorenal Outcomes



Circadian Rhythm, Clock Genes, and Hypertension: Recent Advances in Hypertension


Dose-response effects of physical activity on all-cause mortality and major cardiorenal outcomes in chronic kidney disease.

Cardiorenal Outcomes sentence examples within Beneficial Cardiorenal Outcomes



Up front


The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis

Cardiorenal Outcomes sentence examples within Improving Cardiorenal Outcomes



Role Of Glp-1 Analogs In The Management Of Diabetes And Its Secondary Complication.


Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management


Learn more from Cardiorenal Outcomes 심폐 결과



Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients



Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.



FC 090EFFECTS OF FINERENONE ON CARDIORENAL OUTCOMES IN BLOOD PRESSURE SUBGROUPS IN PATIENTS WITH CKD AND T2D



Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs



Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence



Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators



GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs



791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV



Sodium‐glucose co‐transporter‐2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta‐analysis



Effects and Safety of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomised Controlled Trials



Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF



SGLT2 inhibitors for primary prevention of cardiovascular events



A Prediction Model for Identifying Type 2 Diabetics at Highest Risk of Cardiorenal Outcomes



Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD



Class effects of SGLT2 inhibitors on cardiorenal outcomes



Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial


Learn more from Cardiorenal Outcomes 심폐 결과

Cardiorenal Outcomes 심폐 결과


Cardiorenal Outcomes 심폐 결과
Encyclopedia 백과사전